White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
The White House denied that Trump gained access to Eli Lilly's unapproved obesity drug retatrutide through a compassionate use program. The drug, not yet FDA approved, is available via a program that provides experimental treatments for life-threatening illnesses.
Mentioned
Related Signal
Adjacent reporting
- White House Denies Trump Got Unapproved Obesity Drug
- Doctors prescribing weight loss drug not yet approved by FDA, CBS News investigation finds
- Safety concerns over doctors prescribing experimental weight loss drug not approved by FDA
- STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program